Curis (CRIS) Projected to Post Earnings on Thursday

Curis (NASDAQ:CRIS) is anticipated to post its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Curis to post earnings of ($0.62) per share and revenue of $2.86 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

Curis (NASDAQ:CRIS) last issued its earnings results on Tuesday, August 5th. The biotechnology company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($1.99) by $1.31. The company had revenue of $2.75 million for the quarter, compared to analysts’ expectations of $2.64 million. On average, analysts expect Curis to post $-7 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Curis Stock Performance

NASDAQ:CRIS traded down $0.01 during trading hours on Tuesday, reaching $1.47. The company’s stock had a trading volume of 20,240 shares, compared to its average volume of 94,392. The company has a market capitalization of $18.36 million, a P/E ratio of -0.30 and a beta of 3.86. Curis has a 12 month low of $1.02 and a 12 month high of $5.00. The stock has a 50 day moving average price of $1.63 and a two-hundred day moving average price of $1.85.

Institutional Investors Weigh In On Curis

An institutional investor recently raised its position in Curis stock. Maverick Capital Ltd. lifted its position in shares of Curis, Inc. (NASDAQ:CRIS) by 7.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 681,381 shares of the biotechnology company’s stock after acquiring an additional 49,554 shares during the quarter. Maverick Capital Ltd. owned 5.45% of Curis worth $1,472,000 as of its most recent SEC filing. Institutional investors own 29.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Curis presently has a consensus rating of “Hold” and an average target price of $17.00.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.